Ignite Creation Date:
2024-05-06 @ 7:50 PM
Last Modification Date:
2024-10-26 @ 3:15 PM
Study NCT ID:
NCT06158516
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-12-06
First Post:
2023-11-28
Brief Title:
A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
Sponsor:
Changhai Hospital
Organization:
Changhai Hospital
Study Overview
Official Title:
A Randomized Double-blind Placebo-controlled Multicenter Clinical Trial of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors
Status:
NOT_YET_RECRUITING
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
pNENs still have a risk of recurrence after radical resection and the overall recurrence and metastasis rate is as high as 137-362 in China At present there is no standard adjuvant therapy for pNEN and prospective studies are still lacking This study was a randomized double-blind placebo-controlled multicenter clinical trial to explore the efficacy and safety of surufatinib in the adjuvant treatment of pNET in order to further improve the prognosis of patients and to provide high-quality research evidence for adjuvant therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None